Genetic Polymorphisms and the Cardiovascular Risk of Non-Steroidal Anti-Inflammatory Drugs

American Journal of Cardiology

Volumn 105, Issue 12, 2010, Pages 1740-1745

  Germaine, Christine G St ^a   Bogaty, Peter ^b   Boyer, Luce ^b   Hanley, James ^a   Engert, James C ^a   Brophy, James M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSINOGEN; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; C REACTIVE PROTEIN; CELECOXIB; CYTOCHROME P450 2C9; DICLOFENAC; ENDOTHELIN 1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLOCTAFENINE; GELATINASE B; IBUPROFEN; INTERLEUKIN 18; INTERSTITIAL COLLAGENASE; KLOTHO PROTEIN; MELOXICAM; MESALAZINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTAGLANDIN SYNTHASE; RESISTIN; ROFECOXIB; STROMELYSIN;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CHROMOSOME 9P; DRUG OVERDOSE; FEMALE; GENDER; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOSPITAL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ACUTE CORONARY SYNDROME; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; INFLAMMATION; MALE; MIDDLE AGED; NEW BRUNSWICK; ODDS RATIO; POLYMORPHISM, GENETIC; PROGNOSIS; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77953085608     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.01.352     Document Type: Article

References (29)

1. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
2. Salinas G., Rangasetty U.C., Uretsky B.F., and Birnbaum Y. The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame. J Cardiovasc Pharmacol Ther 12 (2007) 98-111
3. Griffoni C., Spisni E., Strillacci A., Toni M., Bachschmid M.M., and Tomasi V. Selective inhibition of prostacyclin synthase activity by rofecoxib. J Cell Mol Med 11 (2007) 327-338
4. Halushka M.K., Walker L.P., and Halushka P.V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 73 (2003) 122-130
5. Helmersson J., Arnlov J., Axelsson T., and Basu S. A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2alpha formation and lower risk of cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids 80 (2009) 51-56
6. Lee C.R., Bottone Jr. F.G., Krahn J.M., Li L., Mohrenweiser H.W., Cook M.E., Petrovich R.M., Bell D.A., Eling T.E., and Zeldin D.C. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 17 (2007) 145-160
7. Lee Y.S., Kim H., Wu T.X., Wang X.M., and Dionne R.A. Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. Clin Pharmacol Ther 79 (2006) 407-418
8. Bogaty P., Boyer L., Simard S., Dauwe F., Dupuis R., Verret B., Huynh T., Bertrand F., Dagenais G.R., and Brophy J.M. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (Recurrence and Inflammation in the Acute Coronary Syndromes) study. J Am Coll Cardiol 51 (2008) 2339-2346
9. Levesque L.E., Brophy J.M., and Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 174 (2006) 1563-1569
10. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
11. Yamada Y., Matsuo H., Segawa T., Watanabe S., Kato K., Hibino T., Yokoi K., Ichihara S., Metoki N., Yoshida H., Satoh K., and Nozawa Y. Assessment of the genetic component of hypertension. Am J Hypertens 19 (2006) 1158-1165
12. Fries S., Grosser T., Price T.S., Lawson J.A., Kapoor S., DeMarco S., Pletcher M.T., Wiltshire T., and FitzGerald G.A. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 130 (2006) 55-64
13. Rodrigues A.D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug Metab Dispos 33 (2005) 1567-1575
14. Wang X.M., Wu T.X., Lee Y.S., and Dionne R.A. Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors. Clin Pharmacol Ther 79 (2006) 303-315
15. Hage F.G., and Szalai A.J. C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk. J Am Coll Cardiol 50 (2007) 1115-1122
16. Kolz M., Koenig W., Muller M., Andreani M., Greven S., Illig T., Khuseyinova N., Panagiotakos D., Pershagen G., Salomaa V., Sunyer J., and Peters A. DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study. Eur Heart J 29 (2008) 1250-1258
17. Lange L.A., Carlson C.S., Hindorff L.A., Lange E.M., Walston J., Durda J.P., Cushman M., Bis J.C., Zeng D., Lin D., Kuller L.H., Nickerson D.A., Psaty B.M., Tracy R.P., and Reiner A.P. Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA 296 (2006) 2703-2711
18. Araujo M.A., Goulart L.R., Cordeiro E.R., Gatti R.R., Menezes B.S., Lourenco C., and Silva H.D. Genotypic interactions of renin-angiotensin system genes in myocardial infarction. Int J Cardiol 103 (2005) 27-32
19. Tiret L., Godefroy T., Lubos E., Nicaud V., Tregouet D.A., Barbaux S., Schnabel R., Bickel C., Espinola-Klein C., Poirier O., Perret C., Munzel T., Rupprecht H.J., Lackner K., Cambien F., and Blankenberg S. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 112 (2005) 643-650
20. Rhee E.J., Oh K.W., Lee W.Y., Kim S.Y., Jung C.H., Kim B.J., Sung K.C., Kim B.S., Kang J.H., Lee M.H., Kim S.W., and Park J.R. The differential effects of age on the association of KLOTHO gene polymorphisms with coronary artery disease. Metabolism 55 (2006) 1344-1351
21. Shearman A.M., Cooper J.A., Kotwinski P.J., Miller G.J., Humphries S.E., Ardlie K.G., Jordan B., Irenze K., Lunetta K.L., Schuit S.C., Uitterlinden A.G., Pols H.A., Demissie S., Cupples L.A., Mendelsohn M.E., Levy D., and Housman D.E. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res 98 (2006) 590-592
22. Helgadottir A., Thorleifsson G., Manolescu A., Gretarsdottir S., Blondal T., Jonasdottir A., Jonasdottir A., Sigurdsson A., Baker A., Palsson A., Masson G., Gudbjartsson D.F., Magnusson K.P., Andersen K., Levey A.I., Backman V.M., Matthiasdottir S., Jonsdottir T., Palsson S., Einarsdottir H., Gunnarsdottir S., Gylfason A., Vaccarino V., Hooper W.C., Reilly M.P., Granger C.B., Austin H., Rader D.J., Shah S.H., Quyyumi A.A., Gulcher J.R., Thorgeirsson G., Thorsteinsdottir U., Kong A., and Stefansson K. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316 (2007) 1491-1493
23. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., Hinds D.A., Pennacchio L.A., Tybjaerg-Hansen A., Folsom A.R., Boerwinkle E., Hobbs H.H., and Cohen J.C. A common allele on chromosome 9 associated with coronary heart disease. Science 316 (2007) 1488-1491
24. Khoury M.J., and Flanders W.D. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls!. Am J Epidemiol 144 (1996) 207-213
25. Gatto N.M., Campbell U.B., Rundle A.G., and Ahsan H. Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias. Int J Epidemiol 33 (2004) 1014-1024
26. Szalai A.J., Alarcon G.S., Calvo-Alen J., Toloza S.M., McCrory M.A., Edberg J.C., McGwin Jr. G., Bastian H.M., Fessler B.J., Vila L.M., Kimberly R.P., and Reveille J.D. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology (Oxford) 44 (2005) 864-868
27. Timpson N.J., Lawlor D.A., Harbord R.M., Gaunt T.R., Day I.N., Palmer L.J., Hattersley A.T., Ebrahim S., Lowe G.D., Rumley A., and Davey Smith G. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 366 (2005) 1954-1959
28. Elliott P., Chambers J.C., Zhang W., Clarke R., Hopewell J.C., Peden J.F., Erdmann J., Braund P., Engert J.C., Bennett D., Coin L., Ashby D., Tzoulaki I., Brown I.J., Mt-Isa S., McCarthy M.I., Peltonen L., Freimer N.B., Farrall M., Ruokonen A., Hamsten A., Lim N., Froguel P., Waterworth D.M., Vollenweider P., Waeber G., Jarvelin M.R., Mooser V., Scott J., Hall A.S., Schunkert H., Anand S.S., Collins R., Samani N.J., Watkins H., and Kooner J.S. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302 (2009) 37-48
29. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., and Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359 (2008) 1897-1908